eculizumab Archives | The Sumaira Foundation

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments

Posted by: The Sumaira Foundation in

Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD

Posted by: The Sumaira Foundation in

Indirect Treatment Comparison of Ravulizumab Versus Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-Positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P10-14.005)

Posted by: The Sumaira Foundation in

Advances in the long-term treatment of neuromyelitis optica spectrum disorder

Posted by: The Sumaira Foundation in

Alyson’s Story – Silver Lining’s Playbook to NMO

Posted by: The Sumaira Foundation in NMOSD, Patient, Voices of NMO

With a vulnerable yet advocational heart, I would love to re-introduce myself to the NMO community! My name is Alyson Tignor (née Pugh) and I am so much more than […]

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Posted by: The Sumaira Foundation in

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Posted by: The Sumaira Foundation in

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Posted by: The Sumaira Foundation in

Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder

Posted by: The Sumaira Foundation in

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab

Posted by: The Sumaira Foundation in

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Tag: eculizumab

Real-World Efficacy and Safety of Neuromyelitis Optica Spectrum Disorder Disease-Modifying Treatments

Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD

Indirect Treatment Comparison of Ravulizumab Versus Approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-Positive (AQP4-IgG+) Neuromyelitis Optica Spectrum Disorder (NMOSD) (P10-14.005)

Advances in the long-term treatment of neuromyelitis optica spectrum disorder

Alyson’s Story – Silver Lining’s Playbook to NMO

Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab

Industry Partners

Community Partners